OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy. The company was incepted in 2010 and is managed by Jeremy Bastid, CEO and Gilles Alberici, President. The science at OREGA Biotech is based on the research conducted by its academic cofounders Nathalie Bonnefoy, Armand Bensussan and Jean-François Eliaou. Our in vivo screening approach aims at discovering and validating novel immune checkpoint inhibitors and regulators of anti-PD1 response. Our lead asset, an anti-CD39 monoclonal antibody, has been out-licensed to Innate (2016) Pharma and then partnered with AstraZeneca (2018) and its progression in phase 2 clinical trial has been announced in 2022. The second program, at preclinical stage, targets a new regulator of the immune response in order to overcome resistance to anti-PD1 antibodies. The investors are initiative Octalfa, SHAM Innovation Santé, Rhône-Alpes Création and INSERM-Transfert Initiative.
Location: France, Auvergne-Rhône-Alpes, Écully
Member count: 11-50
Total raised: $3.7M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | Turenne Ca... | turennecap... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 21.11.2010 | Series A | $3.7M | - | - |